TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06943521: A Study of MT-4561 in Patients With Various Advanced Solid Tumors

Sponsor: Tanabe Pharma America, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 27 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,295,910

Rescue Site Savings

+$863,940

Unlock Full NCT06943521 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06943521 Rescue Dossier →